Skip to main content

Evidence-Based Supplement Research

Evidence-Based Supplement Research

Pancreatin and Reduced Nonalcoholic Fatty Liver Disease Incidence

Doses used in studies

g/day: 3 (median 3, IQR 3–3) — 1 study

Time to effect

Median: 12.2 months · IQR 12.2 months–12.2 months · Range 12.2 months–12.2 months — Reported in 1 of 1 study

Safety in these studies

adverse eventsNo significant difference
There were no adverse effects.
from: Preventive Effect of High-Dose Digestive Enzyme Management on Development of Nonalcoholic
Overall tolerabilityReported
There were no adverse effects.
from: Preventive Effect of High-Dose Digestive Enzyme Management on Development of Nonalcoholic

1 of 1 paper

Preventive Effect of High-Dose Digestive Enzyme Management on Development of Nonalcoholic Fatty Liver Disease after Pancreaticoduodenectomy: A Randomized Controlled Clinical Trial.
- 2020-12
- RCT
- Journal of the American College of Surgeons 231(6)
- - Koya Yasukawa
  - Akira Shimizu
  - Takahide Yokoyama
  - Koji Kubota
  - Tsuyoshi Notake
  - Hitoshi Seki
  - Akira Kobayashi
  - Yuji Soejima
- PubMed: 32927075
- DOI: 10.1016/j.jamcollsurg.2020.08.761
2 Insights on
- Reduced Nonalcoholic Fatty Liver Disease Incidence
- High evidence
- Clinical
The incidence of NAFLD was significantly lower in the high-dose (8 of 41) compared with the normal-dose (25 of 39) patients (p < 0.001).
Effect
Beneficial
Effect size
Large
Significant
Yes
Dose
3.0 g/day